April 4th 2018
By The Center for Biosimilars Staff
Data suggest that intravitreal bevacizumab increases the risk of thromboembolism, and some studies have raised the possibility of a link between bevacizumab and myocardial infarction (MI), while other studies did not find such a relationship.
March 28th 2018
By Samantha DiGrande
Last week, an overview of systematic reviews and meta-analyses investigating systemic adverse events associated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatments was published in JAMA Ophthalmology.
March 21st 2018
By Kaitlynn Ely
One week after intravitreal bevacizumab injection, corneal endothelial cells showed no sign of inflammation or any other complications, according to a study published in BMC Ophthalmology.
February 19th 2018
While corticosteroids are a common treatment for uveitis, effective corticosteroid-sparing therapies are necessary to maintain disease control without risking corticosteroid-related adverse events.
January 9th 2018
By Jackie Syrop
Intravitreal injection of bevacizumab (Avastin) has revolutionized the treatment of diabetic eye disease, and has emerged as an important treatment modality, either as primary or adjuvant therapy for diabetic macular edema and proliferative diabetic retinopathy.
January 4th 2018
By Kelly Davio
Momenta Pharmaceuticals and Mylan have announced that they will begin a pivotal clinical trial of their jointly developed M710, a proposed biosimilar of the anti–vascular endothelial growth factor (anti-VEGF) therapy aflibercept, referenced on Eylea.
December 12th 2017
A recent study examined whether the use of the anti–tumor necrosis factor agent infliximab could reduce the death of photoreceptors after retinal detachment in an experimental mouse model.
December 3rd 2017
Lucentis (ranibizumab) faces oncoming competition from 4 companies that are developing proposed biosimilars.
November 28th 2017
German drug maker Formycon released its third quarter financial results on Monday, and reported that it plans to launch its biosimilar ranibizumab candidate, FYB201, in the United States in 2020.
November 3rd 2017
Current regulations discourage the use of the more cost-effective bevacizumab and lead to unequal patient access to higher-cost ranibizumab and aflibercept.
